1355249-65-8

Upstream product

• 1355249-61-4 ethyl 3-bromo-1-(4-methoxybenzyl)-1H-pyrazole-4-carboxylate 
• 1355249-62-5 C₁₆H₁₈N₂O₃ 
• 1355249-63-6 C₁₄H₁₄N₂O₃ 

Downstream Products

• 1355249-64-7 C₁₆H₁₉N₃O₃ 
• 1355249-66-9 C₁₈H₂₀N₂O₂ 
• 1355249-67-0 C₁₆H₁₆N₂O₂ 
• 1314140-29-8 2-(4-methoxybenzyl)-5,6,7,8-tetrahydro-2H-cycloheptapyrazol-4-one 
• 1314139-89-3 5-bromo-2-(4-methoxybenzyl)-5,6,7,8-tetrahydro-2H-cycloheptapyrazol-4-one 
• 1314140-32-3 8-(4-methoxybenzyl)-4,5,6,8-tetrahydro-3-thia-1,7,8-triazacyclopenta[e]azulen-2-ylamine 
• 1355249-68-1 C₂₁H₁₉FN₆OS 
• 1355249-76-1 C₁₆H₂₁N₃O₄ 
• 1355249-77-2 C₁₆H₁₈N₂O₃ 
• 1355249-78-3 C₁₆H₁₈N₂O₃ 
• 1355249-79-4 C₁₆H₁₇BrN₂O₃ 
• 1355249-82-9 C₂₀H₂₀N₆O₂S₂ 
• 1355249-83-0 C₁₆H₁₆N₂O₃ 
• 1355249-84-1 C₁₆H₁₈N₂O₃ 

Relevant academic research and scientific papers

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -Cl or -Br. In Formula (II), R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-O-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently -H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (O=), which together with the carbon to which they are attached forms a carbonyl group.